olaparib,bevacizumab
roche,astrazeneca,merck
['olaparib', 'beva ', 'brca']
the right message from paola at esmo should be: no os with olaparib+beva vs beva as 1stline maintenance
in the overall population (median os: 56.5 vs 51.6 mo, hr 0.92; 95% ci 0.76 1.12; p=0.4118). an exploratory analysis , showed os in the hrd or brca+ subgroups. 
De momento, aquí y ahora. 
Después, ya veremos.